CoChat
Sign Up
Cited by 70

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Pulmonary Exacerbations in Adults With Cystic Fibrosis

Stanford, Gemma E., Dave, Kavita, Simmonds, Nicholas J.·2021·Chest
DOI 10.1016/j.chest.2020.09.084PMC PMC7502225
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.chest.2020.09.084

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 4 references

Research works printed but not linked: 62

  1. Bell, 2020, The future of cystic fibrosis care: a global perspective, Lancet Respir Med, 8, 65, 10.1016/S2213-2600(19)30337-6 · DOI
  2. Burgel, 2015, Future trends in cystic fibrosis demography in 34 European countries, Eur Respir J, 46, 133, 10.1183/09031936.00196314 · DOI
  3. Fuchs, 1994, Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group, N Engl J Med, 331, 637, 10.1056/NEJM199409083311003 · DOI
  4. Bilton D, Canny G, Conway S, et al. Pulmonary exacerbation: towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trials. J Cyst Fibros. 2011;10(suppl 2):S79-S81. · DOI
  5. Rabin, 2004, Pulmonary exacerbations in cystic fibrosis, Pediatr Pulmonol, 37, 400, 10.1002/ppul.20023 · DOI
  6. Rosenfeld, 2001, Defining a pulmonary exacerbation in cystic fibrosis, J Pediatr, 139, 359, 10.1067/mpd.2001.117288 · DOI
  7. Ramsey, 1999, Intermittent administration of inhaled tobramycin in patients with cystic fibrosis, N Engl J Med, 340, 23, 10.1056/NEJM199901073400104 · DOI
  8. West, 2017, Standardized Treatment of Pulmonary Exacerbations (STOP) study: physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary exacerbations, J Cyst Fibros, 16, 600, 10.1016/j.jcf.2017.04.003 · DOI
  9. Wielpütz MO, Mall MA. Imaging modalities in cystic fibrosis: emerging role of MRI. Curr Opin Pulm Med. 2015;21(6):609-616. · DOI
  10. Sonneveld, 2015, Lung clearance index in cystic fibrosis subjects treated for pulmonary exacerbations, Eur Respir J, 46, 1055, 10.1183/09031936.00211914 · DOI
  11. Goss, 2007, Patient-reported outcomes in cystic fibrosis, Proc Am Thorac Soc, 4, 378, 10.1513/pats.200703-039BR · DOI
  12. Goss, 2009, Patient-reported respiratory symptoms in cystic fibrosis, J Cyst Fibros, 8, 245, 10.1016/j.jcf.2009.04.003 · DOI
  13. Ferkol, 2006, Cystic fibrosis pulmonary exacerbations, J Pediatr, 148, 259, 10.1016/j.jpeds.2005.10.019 · DOI
  14. Chmiel, 2014, Antibiotic management of lung infections in cystic fibrosis. II. Nontuberculous mycobacteria, anaerobic bacteria, and fungi, Ann Am Thorac Soc, 11, 1298, 10.1513/AnnalsATS.201405-203AS · DOI
  15. Ong, 1989, Infective respiratory exacerbations in young adults with cystic fibrosis: role of viruses and atypical microorganisms, Thorax, 44, 739, 10.1136/thx.44.9.739 · DOI
  16. van Ewijk, 2005, Viral respiratory infections in cystic fibrosis, J Cyst Fibros, 4, 31, 10.1016/j.jcf.2005.05.011 · DOI
  17. Aaron, 2004, Adult cystic fibrosis exacerbations and new strains of Pseudomonas aeruginosa, Am J Respir Crit Care Med, 169, 811, 10.1164/rccm.200309-1306OC · DOI
  18. Flight, 2014, Incidence and clinical impact of respiratory viruses in adults with cystic fibrosis, Thorax, 69, 247, 10.1136/thoraxjnl-2013-204000 · DOI
  19. Cosgriff, 2020, A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis, J Cyst Fibros, 19, 355, 10.1016/j.jcf.2020.04.012 · DOI
  20. Smyth, 2014, European Cystic Fibrosis Society Standards of Care: best practice guidelines, J Cyst Fibros, 13, S23, 10.1016/j.jcf.2014.03.010 · DOI · Paper page
  21. Flume, 2009, Cystic fibrosis pulmonary guidelines, Am J Respir Crit Care Med, 180, 802, 10.1164/rccm.200812-1845PP · DOI
  22. Elphick, 2016, Single versus combination intravenous anti-pseudomonal antibiotic therapy for people with cystic fibrosis, Cochrane Database Syst Rev, 12, CD002007
  23. UK Cystic Fibrosis Trust Antibiotic Working Group. Antibiotic treatment for cystic fibrosis - 3rd edition. https://www.cysticfibrosis.org.uk/∼/media/documents/the-work-we-do/care/consensus-docs-with-new-address/anitbiotic-treatment.ashx?la=en. Accessed November 11, 2020.
  24. Hurley, 2015, Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis, Cochrane Database Syst Rev, 7, CD009730
  25. Bullington, 2019, 1078. Expectations and attitudes toward antimicrobial stewardship among cystic fibrosis care providers, Open Forum Infect Dis, 6, S382, 10.1093/ofid/ofz360.942 · DOI
  26. Lechtzin, 2006, Outcomes of adults with cystic fibrosis infected with antibiotic-resistant Pseudomonas aeruginosa, Respiration, 73, 27, 10.1159/000087686 · DOI
  27. Waters, 2019, Reconciling antimicrobial susceptibility testing and clinical response in antimicrobial treatment of chronic cystic fibrosis lung infections, Clin Infect Dis, 69, 1812, 10.1093/cid/ciz364 · DOI
  28. Zemanick, 2020, Antimicrobial Resistance International Working Group in Cystic Fibrosis. Antimicrobial resistance in cystic fibrosis: a Delphi approach to defining best practices, J Cyst Fibros, 19, 370, 10.1016/j.jcf.2019.10.006 · DOI
  29. Einarsson, 2017, WS03.1 Longitudinal airway microbiota profiling in cystic fibrosis patients enrolled in the CFMATTERS clinical trial, J Cyst Fibros, 16, S4, 10.1016/S1569-1993(17)30168-6 · DOI
  30. Aaron, 2005, Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial, Lancet, 366, 463, 10.1016/S0140-6736(05)67060-2 · DOI
  31. Tümmler, 2019, Emerging therapies against infections with Pseudomonas aeruginosa, F1000 Research, 8, F1000, 10.12688/f1000research.19509.1 · DOI
  32. Wagener, 2013, Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis, Pediatr Pulmonol, 48, 666, 10.1002/ppul.22652 · DOI
  33. Sanders, 2017, Standardized Treatment of Pulmonary Exacerbations (STOP) study: observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations, J Cyst Fibros, 16, 592, 10.1016/j.jcf.2017.04.005 · DOI
  34. Briggs, 2012, Oral antimicrobial use in outpatient cystic fibrosis pulmonary exacerbation management: a single-center experience, Clin Respir J, 6, 56, 10.1111/j.1752-699X.2011.00246.x · DOI
  35. Stanojevic, 2017, Effect of pulmonary exacerbations treated with oral antibiotics on clinical outcomes in cystic fibrosis, Thorax, 72, 327, 10.1136/thoraxjnl-2016-208450 · DOI
  36. Smith, 2018, Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis, Cochrane Database Syst Rev, 10, CD008319
  37. Abbott, 2019, Duration of intravenous antibiotic therapy in people with cystic fibrosis, Cochrane Database Syst Rev, 9, CD006682
  38. Schechter, 2017, Treatment setting and outcomes of cystic fibrosis pulmonary exacerbations, Ann Am Thorac Soc, 15, 225, 10.1513/AnnalsATS.201702-111OC · DOI
  39. Vandevanter, 2016, Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis, J Cyst Fibro, 15, 783, 10.1016/j.jcf.2016.04.005 · DOI
  40. Sanders, 2017, Poor recovery from cystic fibrosis pulmonary exacerbations is associated with poor long-term outcomes, Pediatric Pulmonol, 52, 1268, 10.1002/ppul.23765 · DOI · Paper page
  41. Parkins, 2012, Incidence and risk factors for pulmonary exacerbation treatment failures in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa, Chest, 141, 485, 10.1378/chest.11-0917 · DOI
  42. Burgel, 2017, A first step to STOP cystic fibrosis exacerbations, J Cyst Fibro, 16, 529, 10.1016/j.jcf.2017.08.006 · DOI
  43. Gold, 2019, Correspondence between lung function and symptom measures from the Cystic Fibrosis Respiratory Symptom Diary–Chronic Respiratory Infection Symptom Score (CFRSD-CRISS), J Cyst Fibro, 18, 886, 10.1016/j.jcf.2019.05.009 · DOI
  44. Sequeiros, 2009, Home intravenous antibiotic treatment for acute pulmonary exacerbations in cystic fibrosis—is it good for the patient?, Ann Thorac Med, 4, 111, 10.4103/1817-1737.53346 · DOI
  45. Heltshe, 2018, Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): a trial to compare intravenous antibiotic treatment durations in CF, Contemporary Clinical Trials, 64, 35, 10.1016/j.cct.2017.11.012 · DOI
  46. West, 2018, Unmet needs in cystic fibrosis: the next steps in improving outcomes, Expert Rev Respir Med, 12, 585, 10.1080/17476348.2018.1483723 · DOI
  47. Skolnik, 2018, Recent advances in the understanding and management of cystic fibrosis pulmonary exacerbations, F1000Research, 7, F1000, 10.12688/f1000research.13926.1 · DOI
  48. Hurt, 2014, Inhaled interventions in cystic fibrosis: mucoactive and antibiotic therapies, Respiration, 88, 441, 10.1159/000369533 · DOI
  49. Nevitt, 2018, Inhaled mannitol for cystic fibrosis, Cochrane Database Syst Rev, 2, CD008649
  50. Wark, 2018, Nebulised hypertonic saline for cystic fibrosis, Cochrane Database Syst Rev, 9, CD001506
  51. Yang, 2018, Dornase alfa for cystic fibrosis, Cochrane Database Syst Rev, 9, CD001127
  52. Nevitt, 2018, Inhaled mannitol for cystic fibrosis, Cochrane Database Syst Rev, 2, CD008649
  53. Dentice, 2016, A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis, Thorax, 71, 141, 10.1136/thoraxjnl-2014-206716 · DOI
  54. Ward, 2019, Exercise is commonly used as a substitute for traditional airway clearance techniques by adults with cystic fibrosis in Australia: a survey, J Physiother, 65, 43
  55. Holland, 2003, Non-invasive ventilation assists chest physiotherapy in adults with acute exacerbations of cystic fibrosis, Thorax, 58, 880, 10.1136/thorax.58.10.880 · DOI
  56. Dwyer, 2015, Non-invasive ventilation used as an adjunct to airway clearance treatments improves lung function during an acute exacerbation of cystic fibrosis: a randomised trial, J Physiother, 61, 142
  57. Dovey, 2007, Oral corticosteroid therapy in cystic fibrosis patients hospitalized for pulmonary exacerbation: a pilot study, Chest, 132, 1212, 10.1378/chest.07-0843 · DOI
  58. Heltshe, 2016, Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis, Thorax, 71, 223, 10.1136/thoraxjnl-2014-206750 · DOI
  59. Archangelidi, 2019, Non-invasive ventilation and clinical outcomes in cystic fibrosis: findings from the UK CF registry, J Cyst Fibro, 18, 665, 10.1016/j.jcf.2018.11.006 · DOI
  60. O’driscoll, 2008, BTS guideline for emergency oxygen use in adult patients, Thorax, 63, vi1
  61. Milross, 2019, Non-invasive ventilation versus oxygen therapy in cystic fibrosis: a 12-month randomized trial, Respirology, 24, 1191, 10.1111/resp.13604 · DOI
  62. van Gool, 2013, Understanding the costs of care for cystic fibrosis: an analysis by age and health state, Value Health, 16, 345, 10.1016/j.jval.2012.12.003 · DOI

Cited by

Sorted by citations

See all 70

Metadata

Authors
Stanford, G. E., Dave, K., & Simmonds, N. J.
Venue
Chest
Publisher
Elsevier BV
Published
2021-01
Volume
159
Issue
1
Pages
93-102
ISSN
0012-3692
DOI
10.1016/j.chest.2020.09.084
PMC
PMC7502225
Cited by
70
References
4
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review